In-utero exposure to metformin for type 2 diabetes or polycystic ovary syndrome: A prospective comparative observational study
Reproductive Toxicology Jun 07, 2018
Diav-Citrin O, et al. - A prospective comparative observational cohort study was undertaken to determine the rate of major anomalies after first trimester (T1)-metformin exposure. Researchers prospectively followed-up 170 T1-metformin-exposed pregnancies [119 for diabetes and 51 for polycystic ovary syndrome (PCOS)] and compared them with 93 pregnancies of T1-insulin treated women and 530 non-teratogenic exposed (NTE) pregnancies. No association of metformin first-trimester exposure with a teratogenic risk was observed. The groups with diabetes demonstrated the pattern of anomalies that could be related to hyperglycemia.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries